Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy — Sponsor Intelligence | 8 EU Trials

Filter these 8 trials by condition, phase, country and more.

Open in Search →

8 Registered trials

3 Recruiting

2 Completed trials

1 Countries active

17 Unique IMPs

100% Results reported

Phase III

Phase III/IV

Phase IV

Phase III: 2 Phase III/IV: 2 Phase IV: 4

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Atrial fibrillation 2 Coronary artery disease 1

Top IMPs

AMIODARONE HYDROCHLORIDE 1 BISOPROLOL FUMARATE 1 DAPAGLIFLOZIN 1 EMPAGLIFLOZIN 1 EPLERENONE 1 HEPARIN SODIUM 1 INDAPAMIDE, AMLODIPINE BESILATE, PERINDOPRIL ARGININE 1 METFORMIN HYDROCHLORIDE 1 METOPROLOL TARTRATE 1 OLMESARTAN MEDOXOMIL, AMLODIPINE, HYDROCHLOROTHIAZIDE 1 SEMAGLUTIDE 1 SOTALOL HYDROCHLORIDE 1

All trials

8 total

Strategy To Optimize PeriproCeduraL AnticOagulation in Structural Transseptal Interventions (STOP CLOT Trial) Pending

2024-516376-15-00 Phase III/IV 1 country HEPARIN SODIUM
Optimal Antiplatelet Treatment to Achieve Stroke Avoidance and Fall in Bleeding Events following Left Atrial Appendage Closure (SAFE-LAAC). … Pending

2024-516382-37-00 Phase IV 1 country
Optimal Antiplatelet Treatment to Achieve Stroke Avoidance and Fall in Bleeding Events following Left Atrial Appendage Closure – Chronic Kid… Pending

2024-516384-93-00 Phase IV 1 country
A multiarm, randomized, open label Clinical study comparing AntiatheroSClerotic efficacy of selected Antidiabetic agents in patients with co… Recruiting

2023-508525-27-00 Phase IV 1 country DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SEMAGLUTIDE
Optimal medical treatment of difficult-to-treat hypertension. Recruiting

2024-517628-20-00 Phase III/IV 1 country EPLERENONE; INDAPAMIDE, AMLODIPINE BESILATE, PERINDOPRIL ARGININE; OLMESARTAN ME…
Sacubitril/valsartan in the prevention of disease progression in patients with an ancient arrhythmogenic service - ARNI-ARVC multicentre ran… Recruiting

2024-517412-29-00 Phase III 1 country VALSARTAN, SACUBITRIL
Does the use of empagliflozin improve exercise capacity in patients with hypertrophic cardiomyopathy. Ended

2024-517643-31-00 Phase III 1 country EMPAGLIFLOZIN
Early ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy Ended

2023-508743-43-00 Phase IV 1 country AMIODARONE HYDROCHLORIDE; BISOPROLOL FUMARATE; METOPROLOL TARTRATE; SOTALOL HYDR…

Showing 1–8 of 8 trials

← All sponsors A–Z